• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探讨肿瘤微环境在铂耐药性卵巢癌中的临床价值。

Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.

机构信息

Departments of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC, 27157, USA.

Departments of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC, 27157, USA; Alexandria University School of Medicine, Alexandria, Egypt.

出版信息

Semin Cancer Biol. 2021 Dec;77:83-98. doi: 10.1016/j.semcancer.2020.12.024. Epub 2021 Jan 18.

DOI:10.1016/j.semcancer.2020.12.024
PMID:33476723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8286277/
Abstract

Platinum resistance in epithelial ovarian cancer (OvCa) is rising at an alarming rate, with recurrence of chemo-resistant high grade serous OvCa (HGSC) in roughly 75 % of all patients. Additionally, HGSC has an abysmal five-year survival rate, standing at 39 % and 17 % for FIGO stages III and IV, respectively. Herein we review the crucial cellular interactions between HGSC cells and the cellular and non-cellular components of the unique peritoneal tumor microenvironment (TME). We highlight the role of the extracellular matrix (ECM), ascitic fluid as well as the mesothelial cells, tumor associated macrophages, neutrophils, adipocytes and fibroblasts in platinum-resistance. Moreover, we underscore the importance of other immune-cell players in conferring resistance, including natural killer cells, myeloid-derived suppressive cells (MDSCs) and T-regulatory cells. We show the clinical relevance of the key platinum-resistant markers and their correlation with the major pathways perturbed in OvCa. In parallel, we discuss the effect of immunotherapies in re-sensitizing platinum-resistant patients to platinum-based drugs. Through detailed analysis of platinum-resistance in HGSC, we hope to advance the development of more effective therapy options for this aggressive disease.

摘要

铂耐药性在卵巢上皮癌 (OvCa) 中呈上升趋势,约 75%的化疗耐药性高级别浆液性 OvCa (HGSC) 患者出现复发。此外,HGSC 的五年生存率极差,FIGO 分期 III 期和 IV 期分别为 39%和 17%。在此,我们回顾了 HGSC 细胞与独特腹膜肿瘤微环境 (TME) 的细胞和非细胞成分之间的关键细胞相互作用。我们强调了细胞外基质 (ECM)、腹水以及间皮细胞、肿瘤相关巨噬细胞、中性粒细胞、脂肪细胞和成纤维细胞在铂耐药性中的作用。此外,我们强调了其他免疫细胞在赋予耐药性方面的重要性,包括自然杀伤细胞、髓源性抑制细胞 (MDSCs) 和 T 调节细胞。我们展示了关键铂耐药性标志物的临床相关性及其与 OvCa 中受干扰的主要途径的相关性。同时,我们讨论了免疫疗法在使铂耐药患者重新对铂类药物敏感方面的作用。通过对 HGSC 中铂耐药性的详细分析,我们希望为这种侵袭性疾病开发更有效的治疗选择。

相似文献

1
Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.探讨肿瘤微环境在铂耐药性卵巢癌中的临床价值。
Semin Cancer Biol. 2021 Dec;77:83-98. doi: 10.1016/j.semcancer.2020.12.024. Epub 2021 Jan 18.
2
Targeting the tumour microenvironment in platinum-resistant ovarian cancer.针对铂耐药卵巢癌的肿瘤微环境。
Semin Cancer Biol. 2021 Dec;77:3-28. doi: 10.1016/j.semcancer.2021.02.007. Epub 2021 Feb 16.
3
A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.一种新型细胞系面板揭示了高级别浆液性卵巢癌中铂耐药的非遗传介质和表型多样性。
Gynecol Oncol. 2022 Oct;167(1):96-106. doi: 10.1016/j.ygyno.2022.07.027. Epub 2022 Jul 30.
4
Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.单细胞RNA测序分析揭示了铂敏感和铂耐药高级别浆液性卵巢癌之间不同的转录组事件。
J Gene Med. 2023 Oct;25(10):e3504. doi: 10.1002/jgm.3504. Epub 2023 Apr 26.
5
Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets.铂耐药性卵巢癌的基因组分析:寻找可用药靶的途径。
Semin Cancer Biol. 2021 Dec;77:29-41. doi: 10.1016/j.semcancer.2020.10.016. Epub 2020 Nov 5.
6
Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.卵巢癌相关间皮细胞通过 FN1/Akt 信号通路诱导腹膜转移获得性铂耐药。
Int J Cancer. 2020 Apr 15;146(8):2268-2280. doi: 10.1002/ijc.32854. Epub 2020 Jan 24.
7
Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.上皮性卵巢癌铂耐药:上皮-间充质转化的相互作用与重编程代谢相关联。
J Transl Med. 2022 Dec 3;20(1):556. doi: 10.1186/s12967-022-03776-y.
8
Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NFκB Pathway.化合物C通过PI3K-AKT-mTOR-NFκB信号通路抑制卵巢癌进展。
Cancers (Basel). 2022 Oct 18;14(20):5099. doi: 10.3390/cancers14205099.
9
New approaches for targeting platinum-resistant ovarian cancer.针对铂耐药性卵巢癌的新方法。
Semin Cancer Biol. 2021 Dec;77:167-181. doi: 10.1016/j.semcancer.2020.08.013. Epub 2020 Aug 29.
10
Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape.双重保险应对 OC:miRNA 介导的铂耐药和免疫逃逸。
Front Immunol. 2021 Apr 1;12:641937. doi: 10.3389/fimmu.2021.641937. eCollection 2021.

引用本文的文献

1
Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance.卵巢癌化疗耐药中的信号网络与微小RNA相互作用
J Ovarian Res. 2025 Aug 14;18(1):185. doi: 10.1186/s13048-025-01770-8.
2
Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer.安罗替尼与免疫疗法联合应用可增强高级别浆液性卵巢癌的抗血管生成和免疫反应。
Front Immunol. 2025 Apr 7;16:1539616. doi: 10.3389/fimmu.2025.1539616. eCollection 2025.
3
Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model.

本文引用的文献

1
Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker.肿瘤进展过程中腱生蛋白-X表达缺失:一种新的泛癌标志物。
Matrix Biol Plus. 2020 Jan 20;6-7:100021. doi: 10.1016/j.mbplus.2020.100021. eCollection 2020 May.
2
Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets.铂耐药性卵巢癌的基因组分析:寻找可用药靶的途径。
Semin Cancer Biol. 2021 Dec;77:29-41. doi: 10.1016/j.semcancer.2020.10.016. Epub 2020 Nov 5.
3
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer.
菊苣酸与PD-1/PD-L1阻断剂联合治疗可改善患者来源的卵巢癌异种移植模型中的免疫治疗反应。
Cell Commun Signal. 2025 Mar 14;23(1):137. doi: 10.1186/s12964-025-02146-7.
4
Identifying macrophage-associated subtypes in patients with serous ovarian cancer and exploring potential personalized therapeutic drugs using combined single-cell and bulk RNA sequencing omics.通过联合单细胞和批量RNA测序组学鉴定浆液性卵巢癌患者中与巨噬细胞相关的亚型并探索潜在的个性化治疗药物。
Heliyon. 2025 Feb 7;11(4):e42429. doi: 10.1016/j.heliyon.2025.e42429. eCollection 2025 Feb 28.
5
Complement activation at the interface between adipocytes and cancer cells drives tumor progression.脂肪细胞与癌细胞界面处的补体激活驱动肿瘤进展。
JCI Insight. 2025 Feb 18;10(6):e184935. doi: 10.1172/jci.insight.184935.
6
CK2α-mediated phosphorylation of DUB3 promotes YAP1 stability and oncogenic functions.CK2α介导的DUB3磷酸化促进YAP1稳定性和致癌功能。
Cell Death Dis. 2025 Jan 18;16(1):27. doi: 10.1038/s41419-024-07323-z.
7
Ovarian tumor microenvironment contributes to tumor progression and chemoresistance.卵巢肿瘤微环境促进肿瘤进展和化疗耐药。
Cancer Drug Resist. 2024 Dec 17;7:53. doi: 10.20517/cdr.2024.111. eCollection 2024.
8
Emerging strategies to overcome ovarian cancer: advances in immunotherapy.克服卵巢癌的新兴策略:免疫疗法的进展
Front Pharmacol. 2024 Nov 5;15:1490896. doi: 10.3389/fphar.2024.1490896. eCollection 2024.
9
Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance.解析细胞外囊泡网络:揭示卵巢癌转移和化疗耐药的机制。
Mol Cancer. 2024 Sep 16;23(1):201. doi: 10.1186/s12943-024-02103-x.
10
A Predictive Model for Initial Platinum-Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue-Derived Small Extracellular Vesicles.基于组织来源的小细胞外囊泡预测上皮性卵巢癌术后患者初始铂类化疗疗效的模型。
J Extracell Vesicles. 2024 Aug;13(8):e12486. doi: 10.1002/jev2.12486.
铂耐药卵巢癌免疫治疗的挑战。
Semin Cancer Biol. 2021 Dec;77:127-143. doi: 10.1016/j.semcancer.2020.08.017. Epub 2020 Sep 12.
4
New approaches for targeting platinum-resistant ovarian cancer.针对铂耐药性卵巢癌的新方法。
Semin Cancer Biol. 2021 Dec;77:167-181. doi: 10.1016/j.semcancer.2020.08.013. Epub 2020 Aug 29.
5
Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.从 BRCA1 和 BRCA2 基因突变携带者的上皮性输卵管-卵巢癌中了解化疗耐药的经验教训。
Semin Cancer Biol. 2021 Dec;77:110-126. doi: 10.1016/j.semcancer.2020.08.005. Epub 2020 Aug 19.
6
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.卵巢癌肿瘤免疫微环境(TIME)作为治疗靶点:聚焦先天免疫细胞作为治疗效应物。
Int J Mol Sci. 2020 Apr 28;21(9):3125. doi: 10.3390/ijms21093125.
7
Suppression of ovarian cancer by low-intensity ultrasound through depletion of IL-6/STAT3 inflammatory pathway-maintained cancer stemness.低强度超声通过耗竭 IL-6/STAT3 炎症通路维持的癌症干性抑制卵巢癌。
Biochem Biophys Res Commun. 2020 Jun 4;526(3):820-826. doi: 10.1016/j.bbrc.2020.03.136. Epub 2020 Apr 6.
8
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.五种铂类抗肿瘤药物的耐药机制
Front Pharmacol. 2020 Mar 20;11:343. doi: 10.3389/fphar.2020.00343. eCollection 2020.
9
Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites.代谢因素导致卵巢癌腹水中 T 细胞抑制。
Int J Cancer. 2020 Oct 1;147(7):1768-1777. doi: 10.1002/ijc.32990. Epub 2020 Apr 25.
10
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives.上皮性卵巢癌中的免疫检查点抑制剂:疗效与未来展望概述
Diagnostics (Basel). 2020 Mar 7;10(3):146. doi: 10.3390/diagnostics10030146.